Ampio Pharmaceuticals Inc
OTC:AMPE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ampio Pharmaceuticals Inc
Operating Income
Ampio Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ampio Pharmaceuticals Inc
OTC:AMPE
|
Operating Income
-$9.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$26.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$16.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$19.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$26.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$29.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
Ampio Pharmaceuticals Inc
Glance View
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
See Also
What is Ampio Pharmaceuticals Inc's Operating Income?
Operating Income
-9.5m
USD
Based on the financial report for Dec 31, 2023, Ampio Pharmaceuticals Inc's Operating Income amounts to -9.5m USD.
What is Ampio Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was 53%. The average annual Operating Income growth rates for Ampio Pharmaceuticals Inc have been 16% over the past three years , 3% over the past five years , and 9% over the past ten years .
